Home Capital Broker's Calls

DBS proceeds with ‘buy’ rating for IHH amidst ongoing lawsuit

Chloe Lim
Chloe Lim1/12/2022 3:39 PM GMT+08  • 2 min read
DBS proceeds with ‘buy’ rating for IHH amidst ongoing lawsuit
DBS Group Research analyst Rachel Tan has kept her ‘buy’ rating on IHH with an increased target price of $2.32 from $2.00
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

DBS Group Research analyst Rachel Tan has kept her ‘buy’ rating on IHH with an increased target price of $2.32 from $2.00 previously.

IHH is currently trading at a very attractive FY2022 EV/EBITDA of 14 times, close to -2 standard deviation of its historical range and is positioned to ride on the strong pent-up demand from foreign patients when borders reopen, says Tan.

Earlier on Jan 5, IHH announced that it has been in legal tussles with US fund Emqore Envesecure Private Capital Trust since June 2020.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.